Arcus Biosciences slides 20% on stock offering, kidney-cancer data (RCUS:NYSE)
Coverage across the spectrum
How we rate outletsThe story so far
- Arcus Biosciences prices $250 million stock offering at $17.50.
Who's reporting it
All 3 sourcesTimeline
6h ago
Seeking Alpha (US): Arcus Biosciences slides 20% on stock offering, kidney-cancer data
6h ago
Seeking Alpha (US): Arcus Biosciences slides 20% on stock offering, kidney-cancer data (RCUS:NYSE)
1h ago
Investing.com: Arcus Biosciences prices $250 million stock offering at $17.50
More in Business
Zenith bid goes unconditional as Forrestania builds WA gold stockpile
Multiple outlets • 3h ago
Forrestania Resources has declared its Zenith Minerals takeover bid unconditional, clearing the decks for a bigger WA gold business as it snaps up 400,000 tonnes of ore feed from Star Minerals.
3 sources
‘It’s never been worse’: Vic Market traders slam rotten relations with management
Multiple outlets • 1h ago
Traders and advocates at the Queen Victoria Market say the cultural icon is at risk. Management say it is thriving. Both can’t be right.
2 sources
ASX retreats as energy shares slump; Nick Scali tanks; Westpac axes jobs
Multiple outlets • 2h ago
The Australian sharemarket declined on Thursday, as shares in furniture retailer Nick Scali plummeted after a profit warning.
3 sources
Reader Discussion
Loading comments…